dorsaVi Limited (DVL) AI Stock Analysis

• Market Cap: AU$7.31M
• Dividend Yield: N/A
• Average Volume (3M): 386.39K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.24
• Revenue Growth: -8.28%
• EPS Growth: 35.71%
• Country: AU
• Employees: 34
• Sector: Technology
• Sector Strength: 77
• Industry: Hardware, Equipment & Parts
• EPS (TTM): >-0.01
• Shares Outstanding: 731,237,900
• 10 Day Avg. Volume: 303,095
• 30 Day Avg. Volume: 386,388
• PEG Ratio: -0.36
• Price to Book (P/B): 3.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

dorsaVi Limited is currently in a challenging financial position with declining revenues and persistent losses. The lack of positive cash flow and operational inefficiencies are major concerns. Additionally, the absence of technical data and poor valuation metrics contribute to the low stock score.

dorsaVi Limited Business Overview & Revenue Model

Company Description

dorsaVi Limited (DVL) is a technology company specializing in wearable sensor technology and software solutions that capture and analyze movement and muscle activity. The company operates primarily in the healthcare, occupational health and safety, and sports sectors, providing products and services that help improve clinical outcomes, optimize performance, and enhance workplace safety. Its core products include wearable sensors and accompanying software platforms that offer detailed insights into human movement and ergonomics.

How the Company Makes Money

dorsaVi Limited generates revenue through the sale of its wearable sensor devices and subscription-based access to its software platforms. The company offers its products and services to healthcare providers, sports professionals, and organizations focused on workplace safety, which utilize the technology for injury prevention, rehabilitation, and performance optimization. Additionally, dorsaVi may form strategic partnerships with healthcare institutions, sports organizations, and corporate clients, providing customized solutions that contribute to its earnings. Revenue is also supported by ongoing research and development efforts that enhance the company's product offerings, leading to potential increases in sales and subscription renewals.

dorsaVi Limited Financial Statement Overview

Summary

dorsaVi Limited is facing significant financial challenges with declining revenues, persistent losses, and negative cash flows. While the company maintains a manageable level of debt, the operational inefficiencies and inability to generate positive cash flows pose serious concerns.

Income Statement

dorsaVi Limited has experienced a decline in revenue and profitability over recent years. The negative gross profit margin indicates the company is selling its products below cost. With consistent negative EBIT and EBITDA margins, the company is struggling to cover its operating expenses. Additionally, the company has not shown any revenue growth in the past year, highlighting significant challenges in its business model and market conditions.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, which suggests moderate leverage. However, the persistent losses have eroded equity over the years, and the return on equity remains negative, indicating inefficiencies in using shareholder funds. The equity ratio shows that equity is a small portion of total assets, hinting at potential solvency issues.

Cash Flow

The company has consistently experienced negative free cash flow, indicating it is not generating enough cash to cover its capital expenditures. The operating cash flow is also negative, reflecting challenges in generating cash from core operations. The free cash flow and operating cash flow to net income ratios are unfavorable, suggesting poor cash conversion efficiency.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.35M	1.30M	1.75M	2.35M	1.87M	2.02M
	Gross Profit
576.91K	1.18M	-798.43K	-1.45M	-1.74M	-2.21M
	EBIT
-1.38M	-1.69M	-2.37M	-2.83M	-3.08M	-3.96M
	EBITDA
-1.45M	-1.60M	-1.88M	-1.53M	-2.29M	-6.84M
	Net Income Common Stockholders
-1.14M	-1.25M	-1.82M	-1.54M	-2.41M	-7.59M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.24M	478.10K	878.72K	449.70K	2.80M	1.69M
	Total Assets
2.62M	2.18M	2.69M	3.36M	5.42M	3.83M
	Total Debt
131.48K	190.17K	321.85K	1.18M	1.18M	1.91M
	Net Debt
-1.11M	-287.93K	-556.87K	731.43K	-1.61M	226.63K
	Total Liabilities
938.19K	1.16M	1.01M	2.13M	2.95M	3.37M
	Stockholders Equity
1.68M	1.02M	1.68M	1.22M	2.48M	459.03K
Cash Flow		Free Cash Flow
-711.76K	-622.08K	-1.02M	-2.25M	-2.36M	-2.97M
	Operating Cash Flow
-707.75K	-600.90K	-967.41K	-2.15M	-2.27M	-2.18M
	Investing Cash Flow
-10.02K	-21.18K	-51.65K	-100.34K	-85.41K	-788.80K
	Financing Cash Flow
1.07M	227.06K	1.45M	-92.25K	3.47M	1.89M

dorsaVi Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RHT	64 Neutral	AU$17.47M	140.00	-3.11%	―	89.13%	69.57%
Sector *	60 Neutral	$11.59B	10.34	-7.15%	2.94%	7.49%	-10.88%
RAC	54 Neutral	AU$244.96M	―	-37.20%	―	―	32.02%
BOT	53 Neutral	AU$732.73M	―	-56.99%	―	10.76%	-195.89%
PYC	50 Neutral	AU$699.91M	―	-112.97%	―	―	-84.82%
IPD	49 Neutral	$68.93M	―	-51.08%	―	10.22%	-2.94%
DVL	32 Underperform	AU$7.31M	―	-74.01%	―	-8.28%	35.71%

dorsaVi Limited Corporate Events

dorsaVi Expands AI Platform into Workplace Safety Market

dorsaVi has expanded its AI-powered movement analysis platform, Video AI, into the workplace ergonomics market, partnering with a major US franchise group and a leading Australian insurer. This strategic move allows dorsaVi to leverage its scalable, high-margin Video AI platform to enter the multibillion-dollar workplace safety and injury prevention market, marking a significant milestone in the company’s product evolution.

dorsaVi Advances AI Movement Analysis and Launches New ACL Injury Test

dorsaVi Limited has reported significant progress in the commercial release of its AI-powered Video Movement Analysis Platform, gaining traction in the US market. The company has achieved sales revenue of $289k and is advancing security clearances with a major US clinical group, which could expand its market presence. Additionally, dorsaVi has launched a pioneering 3D motion analysis test to address ACL injuries, potentially setting a new standard in sports medicine. A new research collaboration with a prominent US surgeon aims to optimize movement analysis for elite athletes, further reinforcing dorsaVi’s leadership in data security and injury prevention.

dorsaVi Limited Announces Cessation of Securities

dorsaVi Limited announced the cessation of 4,801,827 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies.

dorsaVi Unveils Revolutionary 3D Motion Analysis to Combat ACL Injuries

dorsaVi has launched a groundbreaking 3D motion analysis test designed to reduce ACL injuries in athletes. This innovative tool, which utilizes FDA-cleared wearable sensors and advanced AI, offers a significant improvement over traditional 1D force plates by capturing critical rotational torque forces. The new technology is expected to open substantial market opportunities in elite sports, rehabilitation centers, and physiotherapy clinics, enabling real-time, laboratory-grade analysis for proactive injury prevention and rehabilitation strategies.

DorsaVi Limited Reports Revenue Growth and Improved Financial Position for H1 2024

DorsaVi Limited reported a 7.9% increase in revenues to $663,925 for the half-year ended December 2024, driven by a rise in one-off revenue contracts. Despite a 15.7% reduction in losses to $578,542, the company maintained its focus on cost rationalization, evidenced by an 8.1% decrease in operating expenditure. The company’s cash position improved significantly, with cash and cash equivalents rising to $1,241,459, and net assets increasing by $655,814, indicating a stronger financial position.